PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patients aged 70 and older
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
colon cancer
Спонсор: Fondation Franc.Cancerologie Digestive
Налично на:
БГ
Обобщение
Trial status: Authorised
The dose intensity, The overall tolerance to the treatments, The time to recurrence, Overall survival, The time to decrease in autonomy, The time to decrease in the quality of life
The primary endpoint is relapse-free survival (RFS). It is defined as the time limit between the randomisation date and the date of the first recurrence (local or remote) or the date of death, regardless of the cause. All second cancers, colon or not, shall not be taken into account. The living patients without recurrence shall be censored at the date of their last assessment.
Описание
The dose intensity, The overall tolerance to the treatments, The time to recurrence, Overall survival, The time to decrease in autonomy, The time to decrease in the quality of life
Кой може да участва
Age group: 65+ years
Gender: Female, Male
Target enrollment: 973 participants
Интервенции
Xeloda 150 mg film-coated tablets
Drug
ELOXATINE 5 mg/ml, solution à diluer pour perfusion
Drug
Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion
Drug
ELVORINE 100 mg/10 mL, solution injectable
Drug
FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion
БГ
EN